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Clinical outcomes for patients presenting with acute ST-
segment elevation myocardial infarction (STEMI) and un-
dergoing primary percutaneous coronary intervention (PCI)
have significantly improved over the last decade (1). These
improvements result from multiple factors, which include
earlier contact for patients with medical staff, better and
faster transportation to PCI hospitals, reduced door-to-
balloon times, rapid oral antiplatelet therapy, and better
anticoagulation regimens. Given these better results, the
quest to further optimize outcomes has proven challenging.
Recent trials using new pharmacological agents, intracoro-
nary platelet glycoproteins IIb/IIIa receptor inhibitors,
intra-aortic balloon pump, or mechanical thrombectomy
have been negative or have produced marginal benefit in
surrogate endpoints (2,3).
See pages 2481 and 2490
In this issue of the Journal the RIVAL (Radial vs.
Femoral Access for Coronary Intervention) (4) and RIFLE-
STEACS (Radial Versus Femoral Investigation in ST
Elevation Acute Coronary Syndrome) (5) investigators re-
port a detailed analysis of the 2 large randomized trials
comparing radial and femoral approaches in patients with
STEMI.
The RIVAL trial was performed in 32 countries and
included 7,021 patients with acute coronary syndromes from
2006 to 2010 (6). RIVAL remains the largest trial compar-
ing the radial versus femoral approach to date. Of note, only
122 patients were recruited in the United States. Initially,
the RIVAL study was a substudy of the CURRENT
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the contents of this paper to disclose.(Clopidogrel Optimal Loading Dose Usage to Reduce
Recurrent Events) trial (no STEMI), which recruited ap-
proximately one-half of its patients before the study con-
tinued on its own. Patients with STEMI began to be
enrolled after the protocol was amended, and 1,958 patients
(28% of the total trial) were included. Results were reported
in 2011, and more recently the authors provided a detailed
analysis comparing results in patients presenting with
STEMI versus those presenting with unstable angina or
non-STEMI. Comparison between the characteristics of
the 2 trials is provided in Table 1. It is important to mention
that the primary outcome for the overall RIVAL trial was
not significantly reduced with the radial approach compared
with the femoral approach (3.7% vs. 4.0%; hazard ratio
[HR]: 0.92; 95% CI: 0.72 to 1.17; p  0.50). The rate of
TIMI (Thrombolysis In Myocardial Infarction) major non–
coronary artery bypass graft (CABG)-related bleeding was
low and identical in both groups at 0.5%. Yet using the
ACUITY (Acute Catheterization and Urgent Intervention
Triage Strategy) major bleeding definition, the researchers
found a significant benefit with the radial approach com-
pared with the femoral approach (1.9% vs. 4.5%; HR: 0.43;
95% CI: 0.32 to 0.57; p  0.0001). In accordance with
recently published meta-analyses, they also found a signif-
icant reduction in vascular complications with the radial
approach (1.4% vs. 3.7%; HR: 0.37; 95% CI: 0.27 to 0.52;
p  0.0001) (7). Two findings in pre-specified subgroups,
however, have generated much discussion. First, the primary
outcome was lower among patients assigned to the radial
approach at high-volume radial centers (HR: 0.49; 95% CI:
0.28 to 0.87; p  0.015). Second, among patients with
STEMI (the subject of the article under discussion), the
radial approach significantly reduced the primary outcome
(3.1% vs. 5.2%; HR: 0.60; 95% CI: 0.38 to 0.94; p 0.026),
as well as all-cause mortality (1.3% vs. 3.2%; HR: 0.39; 95%
CI: 0.20 to 0.76; p  0.006). In the primary PCI popula-
tion, the radial approach produced a 54% relative reduction
in mortality at 30 days compared with the standard femoral
approach. No such benefits were found in patients without
STEMI. Importantly, using the OASIS-5 (Fifth Organi-
zation to Assess Strategies in Acute Ischemic Syndromes)–
derived major bleeding definition (main definition), neither
access site–related nor non–access site–related bleeding were
reduced by the radial approach in patients with and without
STEMI, whereas access site bleeding was reduced in pa-
tients both with and without STEMI with the ACUITY
definitions. Conversely, non–access site–bleeding was sim-
ilar with the radial and femoral approaches in both clinical
scenarios.
The RIFLE-STEACS trial was performed at 4 Italian
centers from 2009 to 2011 (5). Compared with RIVAL,
patients in the RIFLE-STEACS study were at higher
baseline risk because the investigators included patients with
symptom duration up to 24 h as well as patients presenting
with cardiogenic shock. To date, this randomized trial is the
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was possible because informed consent could be given by
family members or relatives. Ultimately, 10% of patients
presented in Killip III/IV class and 8% required intra-aortic
balloon pump during procedures. Importantly, the RIFLE-
STEACS trial was more of a primary PCI trial (99% PCI),
whereas RIVAL was more of a STEMI trial (75%
primary PCI). More patients received 300 mg of a
clopidogrel loading dose prior to PCI, and platelet glyco-
protein IIb/IIIa inhibitors were used in 69% of the RIFLE-
STEACS patients versus 35% in RIVAL STEMI pa-
tients. Bivalirudin was rarely used in the RIVAL trial and in
10% of the patients in RIFLE-STEACS. Reflecting
current practice, 6-F sheaths were used in both trials in
90% of the patients. In RIFLE-STEACS, the radial
approach was associated with a 36% relative reduction in the
primary outcome (13.6% vs. 21%; p  0.003). Importantly,
cardiac death was also reduced with the radial approach
compared with the femoral approach (5.3% vs. 9.2%; p 
0.020). The difference was attributed by the researchers to
the reduction of bleeding (7.8% vs. 12.2%; p  0.026), and
articularly access site bleeding, because no difference in
on–access site bleeding was observed between the 2
roups. It should be noted that using the TIMI non-CABG
Characteristics of the RIVAL STEMI and RIFLE-STEACS TrialsTable 1 Characteristics of the RIVAL STEMI and RIFLE-STEACS
RIVAL STEMI
Period 2006–2010
No. of countries 32
Randomization Central IVRS
No. of patients with STEMI 1,958 (74% primary PCI)
Analysis Pre-specified subgroup analysis (STEMI vs. ACS)
trial
Sample size calculation Initially 10% primary outcome in femoral group
expected 25% reduction with radial approach
Conduct Substudy of CURRENT trial and then stand-alon
sample size
Inclusion STEMI*
Exclusion Cardiogenic shock
Abnormal Allen test
Previous CABG
Peripheral vascular disease
Active bleeding or high risk of bleeding
Operators 50 radial procedures within the previous year
Primary endpoint Death (all-cause), MI, stroke, non-CABG major b
Clinical events Blinded assessment
Definition of major bleeding Main definition: 1) fatal, 2) resulted in transfusi
cells, 3) caused hypotension requiring inotro
surgical intervention, 5) caused severely disa
6) intracranial or intraocular, 7) led to 50 g
ACUITY and TIMI definition. Subcategorized as a
site related
Funding Industry in part and peer-review agencies (Cana
Research)
*The number of hours for symptom onset was not reported for the RIVAL trial.
ACS  acute coronary syndromes; ACUITY  Acute Catheterization and Urgent Intervention Tria
o Reduce Recurrent Events; IABP  intra-aortic balloon pump; INR  international normalized ra
vents; PCI  percutaneous coronary intervention; RIFLE-STEACS  Radial Versus Femoral Inve
ntervention; STEMI  ST-segment elevation myocardial infarction; TIMI  Thrombolysis in Myocaajor bleeding definition, the difference between the 2 eroups was no longer significant (1.8% vs. 2.8%; p 0.399).
owever, in contrast to the RIVAL study, the radial
pproach reduced the risk of blood transfusion in RIFLE-
TEACS.
Although these trials have many differences, both showed
hat the radial approach was associated with a striking
elative reduction in mortality, 44% in all-cause death in
IVAL STEMI and 60% in cardiac death in RIFLE-
TEACS. Should we conclude that the case is closed and
hat the radial approach should now become the preferred
nd standard access site for treating all patients presenting
ith STEMI?
Although the radial approach for diagnostic angiography
nd interventions was described 20 years ago, it is only
ecently that there has been renewed interest in the tech-
ique (8). There is firm and convincing evidence that the
adial approach reduces vascular complications and access
ite–related bleeding, accelerates ambulation, and is largely
referred by patients over the femoral approach (6,9). In an
ra of cost containment, these benefits allow faster hospital
ischarge and hence substantial cost benefits for health
ystems (10). These undisputed benefits create selection bias
radial bias) because patients at higher risk of bleeding are
ypically no longer enrolled in those trials either because of
ls
RIFLE-STEACS
2009–2011
1
Sealed envelopes
1,001 (99% primary PCI)
a larger multicenter Independent prospective randomized study
ed to 6% with an
lpha, 80% power)
9.2% NACE in femoral group vs. 4.5% in radial group
(5% alpha, 80% power)
with recalculated Investigator-initiated and investigator-conducted trial
STEMI within 24 h of symptom onset
Cardiogenic shock with no pulse after IABP or
inotropes
Abnormal Allen or oximetry test
Peripheral vascular disease
INR 2 or severe bleeding diathesis
150 PCI per year and 50% radial PCIs per year
g within 30 days Cardiac death, MI, stroke, target lesion
revascularization, bleeding
Blinded assessment
2 U of red blood
port, 4) required
equelae,
oglobin drop
site and non–access
Main definition: overt and actionable non–CABG-
related bleeding with 3 g/dl hemoglobin drop.
TIMI definition. Subcategorized as access site and
non–access site related
stitute of Health None
tegy; CABG  coronary artery bypass graft; CURRENT  Clopidogrel Optimal Loading Dose Usage
S  interactive voice response system; MI  myocardial infarction; NACE  net adverse clinical
n in ST Elevation Acute Coronary Syndrome; RIVAL  Radial vs. Femoral Access for Coronary
farction.Tria
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patients to randomize. Hence, the risk exists that lower-risk
patients get randomized, and underpowered trials and type
II errors result.
But how can simply changing the arterial access site from
femoral to radial reduce mortality? A simplistic view is that
the reduction in major bleeding is the likely mechanism of
the mortality benefit. Although periprocedural bleeding
after the radial or femoral approach is clearly associated with
worse outcomes, that does not mean that bleeding reduction
might automatically reduce mortality (11,12). Furthermore,
recent evidence suggests that non–access site bleeding is
more deleterious than access site bleeding (13). Two im-
portant observations from the studies can be made: 1) the
impact on bleeding is highly dependent of the definitions
used; and 2) it is likely that the radial approach minimizes
access site bleeding regardless of the definition, but any
impact on non–access site bleeding remains undetermined
and unlikely.
It seems biologically implausible that the reduction of
access site–related bleeding/complications with the radial
approach could explain the 50% relative reduction in
30-day mortality after primary PCI (7,9). Although we do
not have the detailed causes of deaths in RIVAL, they are
provided in the appendix for RIFLE-STEACS. Because
most patients in the radial and femoral arms died early after
PCI and most often from pump failure, it is difficult to
understand the mechanisms by which the radial approach
provided its benefit. Other potential mechanisms of the
benefits of the radial approach could lie in earlier ambu-
lation (lower risk of venous thromboembolism and pul-
monary embolism), rapid hospital discharge (lower risk of
nosocomial infection), lower risk of renal dysfunction
(secondary to periprocedural renal embolization), or
other unknown factors (14).
Although the exact impact of the radial approach on
mortality remains unclear, this should not delay the efforts
to promote and increase the use of the radial approach (15).
Indeed, although the industry has invested hundreds of
millions of dollars to find new pharmacological compounds
or devices, there is no need to develop costly new devices to
practice transradial PCI (16). In fact, this is one of the major
challenges to performing large randomized trials comparing
the radial with femoral approach because the industry has
little incentive to invest in those studies. In the United
States for the first time, investigators at the Duke Clinical
Research Institute have combined industry funding with
funding provided by the Food and Drug Administration
Office of Women’s Health to support the conduct of a
multicenter trial comparing the radial and femoral approach
in women undergoing PCI (SAFE-PCI for Women [Study
of Access Site for Enhancement of PCI for Women];
NCT01406236).
Another teaching point from these 2 studies is the
relationship among radial experience, PCI volumes, and
outcomes. Although RIVAL operators were not primarilyradial operators, the investigators observed better results at
sites with more radial experience, whereas RIFLE-
STEACS operators were using the radial approach in
50% of patients prior to study initiation. Hence, this
might suggest that the benefit observed for the treatment of
patients with STEMI with the radial approach does not
necessarily require expert radial operators and that default
radial operators could even possibly obtain better results. To
maximize benefit, it is crucial that fellows get exposed early
in their training to the radial approach (15). Finally, it
should be noted that crossover from the radial approach
occurred in 5% in both trials. This should remind us that
the radial approach to patients with STEMI should be used
only after adequate training and exposure, but interventional
cardiologists are still required to master both access sites to
provide optimal care to patients presenting with acute
coronary syndromes. Furthermore, given the low participa-
tion of U.S. sites in previous trials comparing radial versus
femoral approaches, there is a need for well-designed,
large clinical trials including patients from the United
States. Meanwhile, ongoing trials comparing radial ver-
sus femoral approaches for patients with STEMI will
soon further define the exact benefits of the radial ap-
proach (STEMI-RADIAL trial [ST Elevation Myocardial
Infarction Treated by Radial or Femoral Approach]
NCT01136187, SAFARI-STEMI trial [Safety and Effi-
cacy of Femoral Access Versus Radial for Primary Percuta-
neous Coronary Intervention in ST-Elevation Myocardial
Infarction] NCT01398254, MATRIX trial [Minimizing
Adverse Haemorrhagic Events by TRansradial Access Site
and Systemic Implementation of angioX] NCT01433627).
Before these data become available, the researchers dis-
cussed here and investigators throughout the world must be
congratulated on providing this important clinical informa-
tion to the cardiology community.
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